Study S002576

A Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Chinese Subjects With Type 2 Diabetes Mellitus and Poor Blood Glucose Control by Diet and Exercise

ClinicalTrials.gov record

Registration

Registration: NCT06777238
Acronym: Optimum 1
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: TRIPLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 274
Start: 2025-01-16
Primary completion: 2026-08-07
Lead sponsor: Gan & Lee Pharmaceuticals.
Conditions: Type 2 Diabetes Mellitus (T2DM)
Interventions: DRUG:GZR18; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Primary Outcome Measure [Baseline, Week 44]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.